Have we built any decent bridges over the last 5 years?
More from Bruce Booth with a realistic (and pessimistic) perspective on diagnostic investments and related challenges.
Further motivation to drive the advancement of molecular diagnostics ever more vigorously.
Mathematical models out-perform doctors in predicting cancer patients responses to treatment.
On-Q-ity, a Cancer Diagnostic Company: R.I.P. | LifeSciVC.
Interesting opinion piece rebutting an open letter from Peter Meldrum, CEO of Myriad, in advance of the Supreme Court's decision on the patentability of BRCA1/BRCA2.